Silva Z, Rabaca J, Luz V, Lourenco R, Salio M, Oliveira A
Cancer Immunol Immunother. 2024; 74(1):9.
PMID: 39487861
PMC: 11531459.
DOI: 10.1007/s00262-024-03863-7.
Yang Y, Zhou Y, Wang J, Zhou Y, Watowich S, Kleinerman E
Cancers (Basel). 2024; 16(19).
PMID: 39409873
PMC: 11482638.
DOI: 10.3390/cancers16193251.
Wang Y, Liu C, Fang C, Peng Q, Qin W, Yan X
Nanomicro Lett. 2024; 17(1):30.
PMID: 39347944
PMC: 11442722.
DOI: 10.1007/s40820-024-01533-y.
Chen L, Rao W, Chen Y, Xie J
Oncol Lett. 2024; 28(5):550.
PMID: 39328277
PMC: 11425031.
DOI: 10.3892/ol.2024.14683.
Maccagno M, Tapparo M, Saccu G, Rumiano L, Kholia S, Silengo L
Med Sci (Basel). 2024; 12(3).
PMID: 39311156
PMC: 11417735.
DOI: 10.3390/medsci12030043.
Feasibility Study for the Use of Gene Electrotransfer and Cell Electrofusion as a Single-Step Technique for the Generation of Activated Cancer Cell Vaccines.
Usaj M, Pavlin M, Kanduser M
J Membr Biol. 2024; 257(5-6):377-389.
PMID: 39133276
PMC: 11584437.
DOI: 10.1007/s00232-024-00320-5.
Boron Neutron Capture Therapy-Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy.
Lv L, Zhang J, Wang Y, Liang H, Liu Q, Hu F
Adv Sci (Weinh). 2024; 11(35):e2405158.
PMID: 39021327
PMC: 11425286.
DOI: 10.1002/advs.202405158.
Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A
J Hematol Oncol. 2024; 17(1):40.
PMID: 38835055
PMC: 11151541.
DOI: 10.1186/s13045-024-01561-6.
Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives.
Ren D, Xiong S, Ren Y, Yang X, Zhao X, Jin J
Comput Struct Biotechnol J. 2024; 23:1833-1843.
PMID: 38707540
PMC: 11066472.
DOI: 10.1016/j.csbj.2024.04.054.
Cancer vaccines in the clinic.
Janes M, Gottlieb A, Park K, Zhao Z, Mitragotri S
Bioeng Transl Med. 2024; 9(1):e10588.
PMID: 38193112
PMC: 10771564.
DOI: 10.1002/btm2.10588.
Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy.
Bakhshi P, Nourizadeh M, Sharifi L, Farajollahi M, Mohsenzadegan M
Cancer Cell Int. 2023; 23(1):270.
PMID: 37951911
PMC: 10638778.
DOI: 10.1186/s12935-023-03108-0.
Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy.
Wang K, Zhang X, Ye H, Wang X, Fan Z, Lu Q
Nat Commun. 2023; 14(1):6748.
PMID: 37875481
PMC: 10598200.
DOI: 10.1038/s41467-023-42155-z.
Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice.
Inamdar S, Suresh A, Mangal J, Ng N, Sundem A, Wu C
Nat Commun. 2023; 14(1):5333.
PMID: 37660049
PMC: 10475105.
DOI: 10.1038/s41467-023-41016-z.
Lipid-hybrid cell-derived biomimetic functional materials: A state-of-the-art multifunctional weapon against tumors.
Liu W, Wu L, Chen C, Zheng H, Gao J, Lu Z
Mater Today Bio. 2023; 22:100751.
PMID: 37636983
PMC: 10448342.
DOI: 10.1016/j.mtbio.2023.100751.
Evaluation of the antitumor activity of moronecidin (Piscidin)-like peptide in combination with anti-PD-1 antibody against melanoma tumor.
Mohammadi M, Hasan-Abad A, Ghasemi A
Iran J Basic Med Sci. 2023; 26(9):1061-1067.
PMID: 37605720
PMC: 10440138.
DOI: 10.22038/IJBMS.2023.69639.15166.
Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine.
Han J, Bhatta R, Liu Y, Bo Y, Elosegui-Artola A, Wang H
Nat Commun. 2023; 14(1):5049.
PMID: 37598185
PMC: 10439884.
DOI: 10.1038/s41467-023-40886-7.
Biomimetic Cell-Derived Nanoparticles: Emerging Platforms for Cancer Immunotherapy.
Hu T, Huang Y, Liu J, Shen C, Wu F, He Z
Pharmaceutics. 2023; 15(7).
PMID: 37514008
PMC: 10383408.
DOI: 10.3390/pharmaceutics15071821.
Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy.
Zhang Y, Hou X, Du S, Xue Y, Yan J, Kang D
Nat Nanotechnol. 2023; 18(11):1364-1374.
PMID: 37500773
PMC: 11282451.
DOI: 10.1038/s41565-023-01453-9.
Targeted Microbubbles for Drug, Gene, and Cell Delivery in Therapy and Immunotherapy.
Navarro-Becerra J, Borden M
Pharmaceutics. 2023; 15(6).
PMID: 37376072
PMC: 10302530.
DOI: 10.3390/pharmaceutics15061625.
An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma.
Wang R, Zhu T, Hou B, Huang X
Mol Ther. 2023; 31(8):2376-2390.
PMID: 37312452
PMC: 10422017.
DOI: 10.1016/j.ymthe.2023.06.005.